Text Size

Leuprolide in Treating Adults With Hypogonadotropism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 1998 by FDA Office of Orphan Products Development.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
University of Chicago
Information provided by:
FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier:
NCT00004438
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: June 1998
History of Changes
  Purpose

RATIONALE: Hypogonadotropism is an abnormal condition caused by decreased production of gonadotropins, a group of hormones that stimulate the parts of the reproductive system that produce and release eggs from the ovaries or sperm from the testicles. Leuprolide may stimulate the production of gonadotropins and be effective in increasing testosterone in men and inducing ovulation in women.

PURPOSE: Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism.


Condition Intervention
Hypogonadism
 Drug: leuprolide

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Study of Leuprolide in Adults With Hypogonadotropism

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 45
Study Start Date: September 1997
Detailed Description:

PROTOCOL OUTLINE: Male patients receive leuprolide subcutaneously every 5 days for up to one year and are followed at weeks 4, 6, 8, and 12, then every 2 months.

Female patients receive leuprolide subcutaneously on days 1, 6, and possibly 11. Patients are followed 2 months after the last injection.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of hypogonadotropism

Men: Small testes, abnormal semen analysis, and subnormal plasma testosterone levels without an elevation in gonadotropin levels

Women: Amenorrhea and subnormal plasma estradiol levels, or lack of cornification of the vaginal mucosa without an elevation in gonadotropin levels OR Hypothalamic amenorrhea in normally estrogenized women with amenorrhea or oligomenorrhea and normal plasma free testosterone and gonadotropin levels

Patients with hyperprolactinemia eligible only if hypogonadotropism persists after correction of hyperprolactinemia by dopamine agonist therapy

--Prior/Concurrent Therapy-- At least 2 months since sex hormone treatment

--Patient Characteristics--

Other:

  • Not pregnant
  • No chronic systemic, metabolic, or endocrine disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004438

Locations
United States, Illinois
University of Chicago Children's Hospital Recruiting
Chicago, Illinois, United States, 60637
Contact: Robert L. Rosenfield     773-702-6432        
Sponsors and Collaborators
FDA Office of Orphan Products Development
University of Chicago
Investigators
Study Chair: Robert L. Rosenfield University of Chicago
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00004438     History of Changes
Other Study ID Numbers: 199/13402, UCCH-8451, UCCH-FDR001473
Study First Received: October 18, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
endocrine disorders
hypogonadism
rare disease

Additional relevant MeSH terms:
Hypogonadism
Gonadal Disorders
Endocrine System Diseases
Leuprolide
Antineoplastic Agents, Hormonal
Antineoplastic Agents
 Therapeutic Uses
Pharmacologic Actions
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013